How Has the Intestine Cancer Therapeutics Market Size Evolved in Recent Years?
The intestine cancer therapeutics market has seen considerable growth due to a variety of factors.
• Notable growth has been observed in recent years in the market size for intestine cancer therapeutics. The market is projected to expand from a worth of $14 billion in 2024 to $15.26 billion in 2025, which represents a compound annual growth rate (CAGR) of 9.0%.
The growth experienced in the historical period can be tied to improvements in medical research, higher occurrences of cancer, development in chemotherapy and radiation therapies, as well as initiatives for early detection and screening, and breakthroughs in genetic and biomarker discoveries.
What Are The Predictions for The Intestine Cancer Therapeutics Market in the Coming Years?
The intestine cancer therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for intestine cancer therapeutics is anticipated to witness considerable growth in the coming years, escalating to $21.15 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%.
This projected growth can be linked to factors such as advances in immunotherapy, precision medicine, personalized treatments, new targeted therapies, and the application of artificial intelligence (AI) in a patient-centered approach. The forecast period will likely see trends including liquid biopsy technology, research in precision medicine and biomarkers, combination treatments, approaches focused on the patient and supportive therapies, as well as the implementation of less invasive surgical methods.
Which Drivers Are Accelerating Growth In The Intestine Cancer Therapeutics Market?
The rise in cases of colorectal cancer syndromes related to heredity is anticipated to stimulate the intestine cancer therapeutics market's expansion. These syndromes, which are groups of genetic conditions, elevate a person's chances of contracting colorectal cancer (cancer of the rectum or colon). The syndromes are crucial to intestinal cancer therapeutics as they provide data linked to particular genetic mutations, thereby markedly increasing the risk of developing colorectal cancer. For instance, the World Health Organization, an intergovernmental organization based in Switzerland, predicted in July 2023 that hereditary colorectal cancer's occurrence is set to significantly rise by 2040, projecting approximately 3.2 million new instances and 1.6 million annual deaths. This denotes a surge of 63% new cases and 73% fatalities compared with current statistics. Consequently, the growing frequency of hereditary colorectal cancer syndromes contributes to the increase in the intestine cancer therapeutics market. A major factor driving the Intestine Cancer Therapeutics Market is the revolution brought about by personalized medicine. Personalized medicine, which adjusts medical choices, proceedings, interventions, and medications to a patient's unique features, is witnessing a surge in demand. This practice enables treatment plans in intestine cancer therapeutics to be modified using each patient's genetic and molecular factors, enhancing treatment efficiency and reducing side effects. For instance, in 2022, the Personalized Medicine Coalition, a professional association in the US, highlighted that the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) that year. Out of 35 therapeutic NMEs, approximately 34%, which is 12 in number, are indexed as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the escalating demand for personalized medicine contributes to the growth of the intestine cancer therapeutics market.
What Are The Core Segments Of The Global Intestine Cancer Therapeutics Market?
The intestine cancer therapeutics market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines
2) By Chemotherapy: Adjuvant Chemotherapy, Neoadjuvant Chemotherapy, Palliative Chemotherapy
3) By Other Treatments: Targeted Therapy, Radiation Therapy, Surgery, Hormone Therapy
Pre-Book The Intestine Cancer Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Intestine Cancer Therapeutics Market?
Leading businesses in the realm of intestine cancer therapeutics are pioneering new solutions like Lonsurf and securing endorsements to reach an expanded customer range and boost sale numbers and revenue. LONSURF is a mixture of two distinct drugs, trifluridine and tipiracil, dedicated towards the treatment of mature patients with metastatic colorectal cancer. For illustration, in August 2023, Taiho Oncology Inc., an American pharmaceutical firm, was granted approval for Lonsurf by the US Food and Drug Administration. Lonsurf is offered in the form of a singular, consumable tablet. Trifluridine functions by restraining the proliferation of cancer cells, and tipiracil augments the effectiveness of trifluridine by warding off its degradation by the human body. The clearance for Lonsurf allows patients suffering from metastatic colorectal cancer and other applicable cancers to have a novel remedial alternative that can potentially enhance results and their quality of living.
Who Are the Key Players In The Intestine Cancer Therapeutics Market?
Major companies operating in the intestine cancer therapeutics market report are:
• Pfizer Inc.
• Johnson & Johnson Private Limited
• Roche Holding AG
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck KGaA
• Mylan N.V.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Cipla Inc.
• Aurobindo Pharma Limited
• Lupin Limited
What Are The Regional Insights Into The Intestine Cancer Therapeutics Market?
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
